Skip to main content

Table 7 SABR-COMET/ROSEL dose constraints

From: A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol

  1. Source: Hurkmans et al., Radiation Oncology 2009, 4:1
Back to article page

BMC Palliative Care

ISSN: 1472-684X

Contact us